Hong Wan, PhDVice President, Drug Metabolism and Pharmacokinetics
Dr. Hong Wan joined BioDuro as Senior Vice President of DMPK. He brings over 25 years of pharmaceutical industry experience from roles at leading organizations including AstraZeneca and Hengrui Pharmaceuticals, with expertise spanning DMPK, bioanalysis, and preclinical safety assessment across small molecules, peptides, ADCs, PROTACs, and other novel modalities. He has contributed to the evaluation of numerous preclinical candidates and led studies enabling multiple IND filing, with several programs advancing to approved drugs. He has authored and co-authored over 50 publications in peer-reviewed journals. In addition, He is Editorial Boards of ADMET/DMPK; Expert Opinion on Drug Metabolism & Toxicology, and the Co-Chair of 9th IAPC International Meeting: Emerging Technologies in Drug Discovery and Development, 2024, Sept 23-25 Shanghai.
• PhD
• 25+ years of industry experience
• Background: AstraZeneca, Hengrui Pharmaceuticals